| Bioactivity | Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4]. |
| Invitro | Tallimustine (0.1-10 μM, 4 h) induces damage to purified SV40 DNA[1].Tallimustine (72 h ) shows cytotoxicity in CEM Cells, with an IC50 of 3.5 nM[1].Tallimustine (25 and 100 nM, 6 days) induces erythroid differentiation of K562 cells[2].Tallimustine (100 nM, 6 days) increases accumulation of γ-globin mRNA in K562 cells[2].Tallimustine (0.5 μg/mL, 1 h) arrests SW626 cells in G2/M phase[3]. Cell Viability Assay[2] Cell Line: |
| In Vivo | Tallimustine (3 mg/kg, i.p.) shows antileukaemic activity in L1210 tumor bearing mice[4]. Animal Model: |
| Name | Tallimustine |
| CAS | 115308-98-0 |
| Formula | C32H38Cl2N10O4 |
| Molar Mass | 697.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999 Oct 19;38(42):14045-55. [2]. Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001 Jun;113(4):951-61. [3]. Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995 Jul 17;62(2):170-5. [4]. Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997 Feb;33(2):284-7. |